Whalen Wealth Management Inc. Acquires Shares of 4,320 Johnson & Johnson $JNJ

Whalen Wealth Management Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,320 shares of the company’s stock, valued at approximately $894,000.

Several other large investors also recently modified their holdings of JNJ. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth $28,000. Semmax Financial Advisors Inc. grew its holdings in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth $41,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,142 shares of company stock valued at $7,360,528 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $238.47 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $574.38 billion, a PE ratio of 21.58, a P/E/G ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The stock has a 50-day moving average price of $240.53 and a two-hundred day moving average price of $214.17.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on JNJ. Citigroup increased their target price on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research report on Friday, January 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $255.00 price objective on shares of Johnson & Johnson in a research report on Monday, March 30th. Loop Capital set a $220.00 price objective on Johnson & Johnson in a research report on Tuesday, January 27th. Finally, Bank of America restated a “neutral” rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $237.57.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Major analyst upgrades and price‑target raises are boosting sentiment — Citigroup raised its JNJ target to $285 (maintained Buy), signaling meaningful upside from current levels. Citigroup Adjusts Price Target on Johnson & Johnson to $285 From $274, Maintains Buy Rating
• Positive Sentiment: Additional analyst support: Guggenheim nudged its target to $244 and TD Cowen reiterated a Buy with a $250 target, adding to buying pressure from institutional research. Guggenheim Adjusts Price Target on Johnson & Johnson to $244 From $240, Maintains Buy Rating
• Positive Sentiment: Regulatory and commercial wins: J&J launched the next‑gen Varipulse/VARIPULSE Pro in Europe after CE Mark clearance, supporting MedTech sales growth. Johnson & Johnson brings next-gen Varipulse PFA catheter to Europe
• Positive Sentiment: Clinical/regulatory pipeline progress: J&J secured a permanent U.S. reimbursement code for INLEXZO (bladder cancer), reported 52‑week efficacy for ICOTYDE in psoriasis, and struck a distribution deal for SIRTURO in Japan — tangible evidence of specialty‑therapies momentum. Johnson & Johnson Updates Key Specialty Therapies And Undervaluation Signals For Investors
• Positive Sentiment: Visibility and flow: coverage in S&P 500 trend pieces and low‑volatility blue‑chip lists is drawing attention from dividend and defensive equity buyers. Johnson & Johnson (NYSE:JNJ) Gains Visibility As S&P 500 Today Trends Shift
• Neutral Sentiment: Technicals/buy‑zone mentions: market commentary (Investors.com) flags JNJ as in/near buy zones — useful for traders but not inherently fundamental. Dow Jones Medical Giant Johnson & Johnson Eyes Latest Buy Point
• Neutral Sentiment: Analyst consensus stays constructive (consensus “Moderate Buy”), which supports a steady bid but limits surprise upside unless fundamentals accelerate. Johnson & Johnson (NYSE:JNJ) Receives Consensus Rating of “Moderate Buy” from Analysts

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.